Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-A1 + MAGE-A3 + NY-ESO-1 vaccine (Penn State University)
- Development stage
- Unknown
- Lead developer
- The Pennsylvania State University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Topical
01
Overview
This is an autologous dendritic cell vaccine developed by Penn State University targeting three cancer-testis antigens: MAGE-A1, MAGE-A3, and NY-ESO-1. The vaccine consists of a patient's own dendritic cells pulsed with overlapping peptides derived from the full-length versions of these proteins. It is designed to stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing these antigens, which are typically found in high-risk pediatric solid tumors like neuroblastoma, osteosarcoma, and rhabdomyosarcoma. In clinical trials, it has been administered alongside imiquimod as a topical adjuvant and sometimes decitabine to enhance antigen expression through demethylation.
- Other names
- MAGE-A1, MAGE-A3, and NY-ESO-1 VaccinePenn State dendritic cell vaccineMAGE-A1, MAGE-A3, NY-ESO-1 Vaccine in High Risk Solid Tumors
Beyond the preview
Go deeper on MAGE-A1 + MAGE-A3 + NY-ESO-1 vaccine (Penn State University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-A1 + MAGE-A3 + NY-ESO-1 vaccine (Penn State University).